Israel Active

The US FDA has given orphan status to Glassia from Israel’s Kamada, to treat Graft-versus-host-disease (GVHD).  Preliminary studies indicate that Glassia may be able to treat and reduce the severity of GVHD, a key life-threatening complication of stem cell transplantation from another person.

Phase II trials of liquid levodopa/carbidopa (LD/CD) (ND0612L) by Israeli biotech NeuroDerm have shown improvements in patients with moderate to severe Parkinson’s disease.

The Israeli app GlassesOff has been tested successfully on 32 Israeli Air Force pilots.  On average, a 35% improvement in visual acuity (sharpness and clarity) was achieved after 3 months of exercises for just 12-15 minutes, three times a week.  GlassesOff improves the brain, not the eyes.

(Thanks to Nevet – ) Hadassah Hospital’s Neurocognitive Center has one of the world’s most innovative models for the management of ADHD.  Hadassah’s diagnosis and therapy practices allow children to live normal lives with their families.

WakeUp is the Israeli-developed natural beverage solution to post-lunch fatigue. WakeUp, from Israel’s Inno-Bev, won the 2014 SupplySide CPG Editors’ Choice Award in the Energy Drink category.   

A multi-center trial is to commence of the innovative diagnosis device developed by Israel’s Exalenz Bioscience to detect liver disease.  The device is already used to examine a patient’s breath in order to detect bacteria in the stomach that causes ulcers.

(Thanks to Israel21c) Israel’s G-Med, the world’s first and only global social-professional network exclusively for physicians, allows doctors anywhere to consult with colleagues, and manage multinational research projects.  Launched in 2013, G-Med now has 20,000 users in over 50 countries.

Israeli biotech PolyPid is raising funds for trials of its BonyPid process and device that can release medication over a long period of time.  Currently, infections of dental implants and fractures may need treating by repeated surgery.  BonyPid needs inserting only once.

Israeli biotech Pharmaseed has initiated a new project bringing Israeli, Jordanian and Swiss researchers together to search for a cure for cutaneous leishmaniasis.  The parasitic disease is common in the Middle East and can cause death in patients with weak immune systems.

Reserves officer Dr. Oren Weisman saved Shaul Hanoni in July after a Hamas mortar severed Shaul’s arm during Operation Protective Edge.  Weeks later, Shaul came to Sheba hospital and found that Dr Weisman was on the surgical team that successfully restored functionality to Shaul’s arm.